Cargando…
Activating transcription factor-2 (ATF2) is a key determinant of resistance to endocrine treatment in an in vitro model of breast cancer
BACKGROUND: Activating transcription factor-2 (ATF2), a member of the leucine zipper family of DNA binding proteins, has been implicated as a tumour suppressor in breast cancer. However, its exact role in breast cancer endocrine resistance is still unclear. We have previously shown that silencing of...
Autores principales: | Giannoudis, Athina, Malki, Mohammed Imad, Rudraraju, Bharath, Mohhamed, Hisham, Menon, Suraj, Liloglou, Triantafillos, Ali, Simak, Carroll, Jason S., Palmieri, Carlo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7667764/ https://www.ncbi.nlm.nih.gov/pubmed/33198803 http://dx.doi.org/10.1186/s13058-020-01359-7 |
Ejemplares similares
-
Beam Jitter Studies at ATF and ATF2
por: Pfingstner, Jürgen, et al.
Publicado: (2013) -
A Cytoplasmic Negative Regulator Isoform of ATF7 Impairs ATF7 and ATF2 Phosphorylation and Transcriptional Activity
por: Diring, Jessica, et al.
Publicado: (2011) -
ATF2 COMMISSIONING
por: Seryi, A, et al.
Publicado: (2010) -
Elucidation of an mTORC2-PKC-NRF2 pathway that sustains the ATF4 stress response and identification of Sirt5 as a key ATF4 effector
por: Li, Ruizhi, et al.
Publicado: (2022) -
ATF2 and ATF7 Are Critical Mediators of Intestinal Epithelial Repair
por: Meijer, Bartolomeus J., et al.
Publicado: (2020)